Background. The involvement of lipids in carcinogenic and developmental processes has been reported in some malignancies, but their roles in gastric cancer remain to be analyzed. In this study, we compared the lipid content of gastric cancer tissue and adjacent nonneoplastic mucosa using imaging mass spectrometry. Methods. Mass spectra were acquired from 12 sections of human gastric cancer tissue and adjacent nonneoplastic mucosa using a matrix-assisted laser desorption-ionization time-of-flight tandem mass spectrometry type mass spectrometer equipped with a 355 nm Nd:YAG laser. Protein expression of lysophosphatidylcholine acyltransferase 1 (LPCAT1), which converts lysophosphatidylcholine (LPC) to phosphatidylcholine (PC) in the presence of acyl-CoA in Lands' cycle, was immunohistochemically analyzed in 182 gastric cancer specimens. Results. The averaged mass spectra from the cancer tissue and nonneoplastic mucosa were identical. Most of the signals that differed between cancer tissue and nonneoplastic mucosa corresponded to phospholipids, the majority of which were PC and LPC. Two signals, m/z 798.5 and 496.3, were higher and lower, respectively, in cancer tissues, predominantly in differentiated adenocarcinoma. A database search enabled identification of the ions at m/z 798.5 and m/z 496.3 as potassium-adducted PC (16:0/18:1) and protonadducted LPC (16:0), respectively. Immunohistochemical analysis revealed that LPCAT1 was highly expressed in cancer lesions compared to nonneoplastic mucosa, predominantly in differentiated adenocarcinoma. LPCAT1 expression levels correlated positively with tumor differentiation and negatively with tumor depth, lymph node metastasis, and tumor stage. Conclusions. Overexpressed LPCAT1 protein in gastric mucosa appears to play important roles in the tumorigenic process of gastric cancer by converting LPC to PC.
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Gastric cancer is of major importance worldwide and the second most common cause of cancer-related death in Japan. 1 Many efforts have been made to improve survival rates, including the development of endoscopic screening systems, surgical techniques, and chemotherapy. As such, the discovery of Helicobacter pylori, a major cause of gastric ulcer, acute and chronic gastritis, and gastric cancer, has dramatically improved our understanding of the pathogenesis of the upper gut. 2 Since then, much research has been conducted to further understand the mechanisms underlying the tumorigenesis and malignant transformation of gastric cancer.
In other gastrointestinal cancers such as colorectal cancer, hepatocellular carcinoma (HCC), and cholangiocarcinoma, unique carcinogenic mechanisms are known to involve food intake and virus infection. [3] [4] [5] Recently, the involvement of lipids in the tumorigenesis and development of some malignancies such as colorectal cancer has been reported. 6 However, the roles of lipids or their alterations in gastric cancers are not well understood.
Recently, imaging mass spectrometry (IMS) using matrix-assisted laser desorption/ionization (MALDI) has been developed in the field of proteomics and metabolomics. [7] [8] [9] [10] [11] [12] [13] [14] [15] MALDI-IMS enables visualization of lipid molecule distribution directly from heterogeneous tissue samples by determining differences in the mass-to-charge ratios (m/z). Furthermore, using tandem mass spectrometry (MS/MS analysis), molecules in tissues can be identified by providing detailed structural information.
In this study, we compared the lipid content of gastric cancer tissue and adjacent nonneoplastic mucosa using MALDI-IMS to address the roles of lipid alterations in the tumorigenesis and development of gastric cancer.
MATERIALS AND METHODS

Patients and Tumors
Human gastric cancer tissues were provided by the Diagnostic Pathology Division and Second Department of Surgery, Hamamatsu University School of Medicine. This study was performed in accordance with the guidelines for pathologic specimen handling, which was approved by the ethical committee of Hamamatsu University School of Medicine. No patients had received preoperative therapy before gastrectomy. Patients with stage II or III gastric cancer received adjuvant chemotherapy with S-1 after surgery.
Sample Preparation
Gastric cancer tissues were snap frozen in liquid nitrogen and stored at -80°C. After incubation for 30 min at -20°C, tissue blocks were mounted onto the specimen disc of a cryostat (CM1950; Leica Microsystems, Wetzler, Germany) without embedding by OCT compound to avoid any effects of residual polymer on mass spectra. Tissue sections were sliced to a thickness of 8 lm using a cryostat and mounted onto indium tin oxide-coated glass slides (Bruker Daltonics, Bremen, Germany).
Matrix Application
A thin matrix layer was applied to the surface of samples using an airbrush with a 0.2 mm nozzle (Procon Boy FWA Platinum; Mr. Hobby, Tokyo, Japan). A total of 500 lL of 2,5-dihydroxybenzoic acid solution (50 mg/mL in 70 % methanol/0.1 % trifluoroacetic acid) was sprayed with the distance between the nozzle and the tissue surface maintained at 15 cm.
Imaging of Tissue Sections by MALDI-IMS
Mass spectra were acquired using a matrix-assisted laser desorption-ionization time-of-flight tandem mass spectrometry (MALDI-TOF/TOF) mass spectrometer (Ultraflex II; Bruker Daltonics) equipped with a 355 nm Nd:YAG laser. To install the indium tin oxide-coated glass slides in the ionization chamber, we used a special holder (MTP Slide Adapter II; Bruker Daltonics) with concavities. Spectra were acquired in positive ion mode in the range of 400-1200 m/z. Mass spectra were externally calibrated using bradykinin peptide fragment (amino acid residues 1-7, m/z 757.40; Sigma Aldrich, St. Louis, MO, USA), human angiotensin-II peptide fragment (amino acid residues 18-39, m/z 1046.54; Sigma Aldrich), and matrix (m/z 155.03).
In the imaging experiment, 200 laser shots per point were irradiated (1 s per point); the interval of data points was 150 lm. These mass spectra were acquired from each spot with flexControl 3.0 (Bruker Daltonics). The absolute intensity of mass spectra was processed using adequate normalization because the ionization efficiency of an analyte on tissue sections varies depending on the matrixanalyte co-crystallization conditions. Ion images were reconstructed from the spectra using flexImaging 2.1 (Bruker Daltonics). For each section, two different portions, one from the cancer lesion and the other from the nonneoplastic mucosa, were used to obtain spectra. The two-dimensional image obtained was compared to the hematoxylin and eosin staining of a nearby section ( Supplementary Fig. S1 ).
Tissue Lipid Identification
MS/MS analyses were acquired using a quadrupole time-of-flight (TOF) tandem mass spectrometer (QSTAR Elite; Applied Biosystems/MDS Sciex, Thornhill, ON, Canada) in positive ion mode. The data acquisition conditions were adjusted to obtain good-quality mass spectra with high intensity and signal-to-noise ratios in the fragmented peaks. Mass spectra were obtained and accumulated, and lipid databases such as Lipid Search and Human Metabolome Database were used to determine the structure of identified lipid molecules.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were cut into sections. 4 lm thick and deparaffinized. After rehydration, slides were incubated at 96°C for 40 min in 10 mM sodium citrate buffer, pH 6.0, and then cooled on the bench for 60 min. Sections were incubated in 3 % hydrogen peroxide for 30 min and washed in phosphate-buffered saline. A polyclonal antibody against lysophosphatidylcholine acyltransferase 1 (LPCAT1; Proteintech Group, Chicago, IL, USA) was used as the primary antibody at a dilution of 1:300. N-Histofine Simple Stain MAX-PO (Nichirei Biosciences, Tokyo, Japan) was used as the secondary antibody. The sections were exposed to diaminobenzidine for 7 min, lightly counterstained with hematoxylin, and mounted using a permanent mounting medium. All slides stained with LPCAT1 were reviewed independently by two of the authors with no knowledge of the clinical data. The staining intensity of LPCAT1 was scored as 0 (none), 1? (weak), 2? (moderate), or 3? (strong) ( Supplementary Fig. S2 ) according to previous studies. 16, 17 When heterogeneity was seen, the evaluation was made in the predominant area. Scores of 0 and 1? were defined as LPCAT1-low, and scores of 2? and 3? were defined as LPCAT1-high.
Statistical Analysis
Statistical significance of differences was assessed by Student's t test or the Wilcoxon signed rank test. The association between clinicopathologic data and LPCAT1 expression was evaluated by the Chi square test. Patients' disease-free survival (DFS) and overall survival (OS) were calculated by the Kaplan-Meier method, and statistically significant differences were identified using the log rank test. Differences were considered to be significant at P \ 0.05.
RESULTS
MALDI-IMS of Gastric Cancer Samples
To identify differences in the lipid distribution between cancer lesions and nonneoplastic mucosa, we analyzed 12 tissue sections of gastric cancer by MALDI-IMS. As shown in Fig. 1a , averaged spectra from paired cancer lesions and nonneoplastic mucosae were distinguishable. Among the signals, we focused on one at m/z 798.5, the intensity of which was extremely high in the cancerous lesions (Fig. 1a) . The ion image showed that the intensity at m/z 798.5 was diffusely higher in cancer lesions than in adjacent nonneoplastic mucosa (Fig. 1b) . We also focused on the signal at m/z 496.3, the intensity of which was low in cancer lesions (Fig. 1a, b) . Of note, most spectra obtained from the cancer lesions and nonneoplastic mucosa corresponded to phospholipids. The majority of such signals were estimated to be phosphatidylcholine (PC) and lysophosphatidylcholine (LPC).
Structural Determinations of PC and LPC by MS/MS Analyses
MS/MS analyses were performed to determine the structure of peaks at m/z 798.5 and m/z 496.3 (Fig. 2a) . From the precursor ion at m/z 798.5, product ions at m/z 739.5, m/z 615.5, and m/z 577.5 were detected (Fig. 2a,  left) 18 The NL of 38 Da corresponds to the replacement of adduct ion to PC from potassium (K) to proton (H). These NLs have been shown to be detectable by MS/MS analysis of potassium-adducted PC species. ? . 23 MS/MS analyses using our IMS system were able to detect the ion product at m/z 542.2 that represents the NL (256 Da) of the fatty acid (16:0) from the precursor ion of m/z 798.5. Therefore, the ion at m/z 798.5 was specifically identified as potassiumadducted PC (16:0/18:1) (Fig. 2b, top) .
From the precursor ion at m/z 496.3, ion products at m/z 184.1 and m/z 313.3 were detected (Fig. 2a, right ). An NL of 183 Da from the precursor ion corresponds to the headgroup. Thus, the fragment peaks at m/z 184.1 and m/z
correspond to [PC headgroup ? H]
? and an NL of 183 Da from a precursor peak, respectively. From the results of the database search, we identified the ion at m/z 496.3 as proton-adducted LPC (16:0) (Fig. 2b, bottom) . (Fig. 3) . When analyzing all 12 samples, LPC (16:0) ? H and PC (16:0/18:1) ? K were significantly lower and higher, respectively, in cancerous lesions than nonneoplastic mucosa (Fig. 3, left) . Interestingly, LPC (16:0) ? H and PC (16:0/18:1) ? K were comparable between undifferentiated adenocarcinomas and adjacent nonneoplastic mucosae, whereas those in differentiated adenocarcinomas were significantly lower and higher, respectively, than in adjacent nonneoplastic mucosae (Fig. 3, right and middle) .
Immunohistochemistry of LPCAT1 in Primary Gastric Cancers
Next, we sought to investigate whether the ratio of LPC (16:0) ? H and PC (16:0/18:1) ? K in primary gastric cancer is associated with clinicopathologic features. It is difficult to obtain sufficient numbers of fresh specimens for qualification by MALDI to enable comparisons with patient data. Thus, we decided to analyze the expression levels of LPCAT1, a protein known to convert LPC to PC in the presence of acyl-CoA in Lands' cycle. [24] [25] [26] [27] We stained 182 primary gastric cancer samples, including 12 tissues used for MALDI-IMS, for LPCAT1 protein. lesions compared to nonneoplastic mucosae, regardless of histologic type (P \ 0.05; Fig. 4) . Furthermore, LPCAT1 expression was significantly higher in differentiated adenocarcinoma than undifferentiated adenocarcinoma (P = 0.0058; Fig. 4 ). These changes in LPCAT1 expression appear to be consistent with alterations of LPC (16:0) ? H; PC (16:0/18:1) ? K in cancer lesions was observed predominantly in differentiated adenocarcinomas.
Relationship between LPCAT1 Expression in Primary Gastric Cancers and Clinicopathologic Features
We then compared the expression levels of LPCAT1 protein and clinicopathologic features in 182 primary gastric cancers. Because the numbers of LPCAT1 intensity scores of 0 and 3? were very small in gastric cancer lesion, we classified LPCAT1 scores into two groups: low with score 0-1 and high with 2-3. In addition to pathologic type, LPCAT1 expression levels were negatively correlated with tumor depth, lymph node metastasis, and tumor stage (Table 1) . 
FIG. 4
Immunohistochemistry of LPCAT1 in 182 primary gastric cancers. LPCAT1 expression was significantly higher in cancer lesions compared to nonneoplastic mucosae, and also significantly higher in differentiated adenocarcinoma than undifferentiated adenocarcinoma (P = 0.0058). N nonneoplastic mucosa, C cancer tissue. *P \ 0.05 * P \ 0.05, ** P \ 0.001, *** P \ 0.0001 S210 T. Uehara et al.
Correlation of LPCAT1 Expression in Primary Gastric Cancers with Patient Survival
Of the 182 primary gastric cancers, 169 were at pathologic stage I to III without synchronous metastasis. Univariate analysis of DFS and OS showed that tumor depth, existence of lymph node metastasis, and tumor stage were significantly associated with poor survival (Supplementary Table S1 ). There was no correlation between LPCAT1 expression levels and DFS or OS ( Fig. 5 ; Supplementary Table S1 ).
DISCUSSION
Recently, genetic and epigenetic changes and protein alterations in many malignancies have been revealed by dramatically improved genomic and proteomic techniques. In contrast, alterations of lipids in cancers are not well understood, although recent reports demonstrated theirs roles in some cancers. 28 It is often difficult to analyze lipid alterations using clinical samples because lipids are indissoluble, undetectable by antibody, and poorly detected in formalin-fixed, paraffin-embedded samples owing to losses during the fixation process. In this study, we use MALDI-IMS, which enabled us to visualize lipid levels without destroying pathologic conformation and locoregional information and thus address lipid alterations in gastric cancer tissues.
More than 1000 types of lipid membrane have been identified, and the ratio of these lipids in human cells differs among organs, tissues, cells, and organelles. 29 The fluidity of live membranes is known to be elevated when the ratio of nonsaturated fatty acids increases. 30 Phospholipids such as a PC act as messengers in the cell membrane and alterations of membrane phospholipid levels can influence cell proliferation and viability. 31, 32 In the current study, most signals that differed between gastric cancer tissue and adjacent nonneoplastic mucosa corresponded to PC and LPC. These changes in lipid content may affect membrane fluidity and signal transduction in cancer cells, thereby playing important roles in the tumorigenesis or progression of gastric cancer. We focused on two signals, m/z 798.5 and m/z 496.3, which were higher and lower, respectively, in cancer tissues, and identified as potassiumadducted PC (16:0/18:1) and proton-adducted LPC (16:0), respectively. The oncologic functions of PC and LPC will be evaluated in future in vitro and in vivo studies.
LPCAT1 is highly overexpressed in colorectal adenocarcinomas, HCC, lung cancer, and prostate cancer. 6, 16, [33] [34] [35] In the present study, we found for the first time that LPCAT1 protein expression levels were higher in gastric cancer tissue than in adjacent nonneoplastic mucosa. Interestingly, LPCAT1 overexpression was predominant in differentiated adenocarcinoma, suggesting that LPCAT1 is more likely to play important roles in the tumorigenesis of differentiated adenocarcinoma compared to undifferentiated adenocarcinoma. This dependency on histologic type may represent a characteristic of gastric cancer. Undifferentiated adenocarcinoma can arise de novo from normal mucosa or originate from differentiated adenocarcinoma via dedifferentiation. 36, 37 The expression levels and roles of LPCAT1 in undifferentiated adenocarcinomas may be dependent on tumorigenic pathways. In addition to the overexpression of LPCAT1 protein, increases in the ratio of PC (16:0/ 
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Number of patients at risk FIG. 5 Correlation of LPCAT1 expression with patient survival in 169 primary gastric cancers. LPCAT1 expression was classified into two groups: low, with score 0-1 (n = 47), and high, with score 2-3 (n = 122). There was no correlation between LPCAT1 expression levels and DFS or OS 18:1) ? K was dominant in differentiated adenocarcinomas. In general, undifferentiated gastric cancer is more likely to show an invasive phenotype than differentiated cancer. 38, 39 This distinct lipid alteration may affect morphologic and oncologic phenotypes of gastric cancer cells and shape the characteristic differences between differentiated and undifferentiated carcinomas by altering the membrane conformation of cancer cells. In our earlier report, LPCAT1 overexpression was shown to promote cell proliferation, migration, and invasion of HCC cell lines, while LPCAT1 knockdown resulted in the converse. 33 In the present study, we did not address whether LPCAT1 affects cell proliferation, migration, or invasion of gastric cancer cells. As LPCAT1 protein expression levels were lower in advanced gastric cancer at a higher stage, LPCAT1 may not function or may act negatively in the malignant transformation of gastric cancer. In fact, there was no correlation between LPCAT1 expression levels and DFS or OS. LPCAT1 appears to play roles that are more important early in the developmental process rather than in the progression of gastric cancer.
CONCLUSIONS
Using MALDI-IMS, we found that LPC (16:0) ? H and PC (16:0/18:1) ? K were lower and higher, respectively, in gastric cancers compared to their adjacent nonneoplastic mucosae. Consistently, LPCAT1 expression was higher in gastric cancers, predominantly in differentiated adenocarcinomas. LPCAT1 expression levels correlated positively with tumor differentiation and negatively with tumor depth, lymph node metastasis, and tumor stage.
